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baumannii infections. Tigecycline, a glycylcycline antibiotic, is
active against A. baumannii and it has been used in the treatment
of VAP caused by this pathogen in some countries or regions.
CS5-03 MDR, XDR, and PDR Gram-Negative Bacterial
Infections: An Evolving Global Public Health
Problem
Matthew E. Falagas*. Director, Alfa Institute of Biomedical
Sciences, Athens, Greece; Adjunct Associate Professor of
Medicine, Tufts University School of Medicine, Boston,
Massachusetts, USA
The advanced antimicrobial resistance of Gram-negative bacilli
(mainly A. baumannii, Pseudomonas aeruginosa, and extended
spectrum beta-lactamase producing Enterobacteriaceae, includ-
ing Klebsiella pneumoniae) has become a global public health
threat. The intrinsic or acquired antimicrobial resistance in these
clinically important pathogens is mediated with various mech-
anisms (production of beta-lactamases and/or enzymes inacti-
vating aminoglycosides, efﬂux pumps, lower permeability of the
outer membrane, mutations in antibiotic targets, etc.). Broad-
spectrum beta-lactam antibiotics have been considered the ﬁrst
choice for the treatment of patients with multiple drug resistant
A. baumannii and Pseudomonas aeruginosa infections. However,
the worrisome pattern of increasing antimicrobial resistance of
these pathogens has led to re-evaluation and use of intravenous
and aerosolized polymyxins (mainly colistin) in various parts of
the world. In addition, various agents with novel mechanisms
of antibacterial action have been investigated, although there
are no available clinical data regarding their effectiveness and
safety. Also, the developments in the advancing pattern of
antimicrobial resistance of Gram-negative bacilli has been asso-
ciated with the use of a diversity of deﬁnitions of multiple drug
resistant (MDR), extensively drug resistant (XDR), and pandrug
resistant (PDR) pathogens on which we have commented (Falagas
ME et al. Clin Microbiol Infect 2005;11:1049, J Med Microbiol
2006;55:1619, and Clin Infect Dis 2008;46:1121). Considering
various issues, the terms “pandrug resistance”, “extensive drug
resistance”, and “multidrug resistance” should designate resis-
tance of a pathogen to all, resistance to all but 1 or 2, and
resistance to at least three, respectively, classes of antimicrobial
agents, among those that are available at the time of use of
the deﬁnition in most parts of the world and are regarded as
potentially effective against the respective pathogen.
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Background and aims: Leishmaniasis is caused by parasitic proto-
zoa of the genus Leishmania; humans are infected via the bite of
phlebotomine sandﬂies. It is prevalent in 88 countries, affecting
an estimated 12 million people with approximately 2 million new
cases per year, 500,000 of which are Visceral Leishmaniasis (VL)
and l,500,000 Cutaneous form (CL), representing a signiﬁcant
rank among communicable diseases. Moreover, Leishmania/HIV
coinfection has been reported in 35 countries worldwide. There
are four main types of the disease: In CL, skin ulcers usually
form on exposed areas, which usually heal within a few months,
leaving scars. Diffuse cutaneous leishmaniasis (DCL) produces
disseminated and chronic skin lesions resembling those of lep-
romatous leprosy which is difﬁcult to treat. In muco-cutaneous
form (MCL), the lesions can partially or totally destroy the
mucous membranes of nose, mouth and throat cavities and sur-
rounding tissues. VL is characterized by high fever, substantial
weight loss, swelling of the spleen/liver and anaemia with high
fatality rate within two years. The aim of this study is to analyze
current situation of leishmaniasis as a neglected tropical disease
in the world, Eastern Mediterranean Region and Iran.
Methods: The global burden of leishmaniasis was discussed with
respect to ﬁnancial and political impacts; relation to poverty;
stigma of pathologies; effective implemented tools, available re-
sources and lack of input from pharmaceutical and biotechnology
companies to develop new drugs and vaccines. Criteria by which
different types of leishmaniasis could be prioritized as target
disease were set. These criteria included: incidence, prevalence
and severity of the disease, lack of response to available drugs;
the impact of treatment of individuals on control of transmission
and lack of other major parties involved in drug development.
There are no adequately effective therapies, but some encour-
aging results have been obtained with immuno-modulators plus
antimonials and herbal extracts. Immunogenicity clinical trials
are currently ongoing with whole killed Leishmania parasites,
second generation and DNA vaccines.
Results: According to the current data, the overall inci-
dence/prevalence rates, and social/ﬁnancial burdens of leish-
maniasis are high. The analysis of published trials indicates that
the available drugs are inadequate; the quality of most trials is
poor and requires both improvement and standardization. The
mechanism for controlling Leishmania infection to reach a stable
self healing process is a balanced immune response, however
immune stimulation during chemotherapy can enhance cure.
Conclusions: Neglected tropical diseases are a symptom of
poverty and disadvantage. With little political voice, neglected
leishmaniasis has a low proﬁle and status in public health pri-
orities. In addition, the problem of Leishmania/HIV coinfection
is spreading to the countries that are the world’s major foci of
leishmaniasis. There is an urgent need for new treatments for all
leishmaniasis. Immuno-chemotherapy with therapeutic vaccines
or immunomodulators has a strong potential to make an impact
as a new therapy with shortening duration and reducing dose
of drug treatment and preventing resistance. There is also a
need for safe, affordable and efﬁcacious novel chemotherapeu-
tics. The quality of clinical trials needs to be enhanced and
standardized.
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Background: Falciparum malaria is the most deadly among the
four main types of human malaria. Although great success has
been achieved since the launch of the National Malaria Control
Programme in 1955, malaria remains a serious public health
problem in China. This paper aimed to analyse the geographic
distribution, demographic patterns and time trends of falciparum
malaria in China.
Methods: The annual numbers of falciparum malaria cases dur-
ing 1992-2003 and the individual case reports of each clini-
cal falciparum malaria during 2004-2005 were extracted from
communicable disease information systems in China Center for
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Diseases Control and Prevention. The annual number of cases
and the annual incidence were mapped by matching them to
corresponding province- and county-level administrative units in
a geographic information system. The distribution of falciparum
malaria by age, gender and origin of infection was analysed.
Time-series analysis was conducted to investigate the relation-
ship between the falciparum malaria in the endemic provinces
and the imported falciparum malaria in non-endemic provinces.
Results: Falciparum malaria was endemic in two provinces of
China during 2004-05. Imported malaria was reported in 26
non-endemic provinces. Annual incidence of falciparum malaria
was mapped at county level in the two endemic provinces of
China: Yunnan and Hainan. The sex ratio (male vs. female) for
the number of cases in Yunnan was 1.6 in the children of 0-15
years and it reached 5.7 in the adults over 15 years of age. The
number of malaria cases in Yunnan was positively correlated with
the imported malaria of concurrent months in the non-endemic
provinces.
Conclusion: The endemic area of falciparum malaria in China has
remained restricted to two provinces, Yunnan and Hainan. Stable
transmission occurs in the bordering region of Yunnan and the
hilly-forested south of Hainan. The age and gender distribution in
the endemic area is characterized by the predominance of adult
men cases. Imported falciparum malaria in the non-endemic
area of China, affected mainly by the malaria transmission in
Yunnan, has increased both spatially and temporally. Speciﬁc
intervention measures targeted at the mobile population groups
are warranted.
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Aims: Several recent discoveries of the hallmark features of
programmed cell death (PCD) in Plasmodium falciparum have
presented the possibility of revealing novel targets for anti-
malarial therapy. In this study, we aim to identify drug-induced
PCD pathways and molecular mediators in P. falciparum.
Methods & Results: Using a combination of cell-based assays,
ﬂow cytometry and ﬂuorescence microscopy, we detected
features including mitochondrial dysregulation, activation of
caspase-like proteases and in situ DNA fragmentation in parasites
induced with the antimalarial chloroquine (CQ) and apoptosis
inducer staurosporine (ST). The use of the pan-caspase inhibitor,
z-Val-Ala-Asp-fmk (zVAD), and the mitochondria outer membrane
permeabilization (MOMP) inhibitor, 4-hydroxy-tamoxifen,
enabled the characterization of a novel chloroquine-induced
pathway linking caspase-like protease activation to downstream
mitochondrial dysregulation, ampliﬁed protease activity and
DNA fragmentation. The PCD features were observed only at
high (μM) concentrations of CQ. The use of a new synthetic
ﬂuorophore-labeled chloroquine (FP-CQ) showed that these fea-
tures may be due to concentration-dependent differences in drug
localization. By further using cysteine protease inhibitors z-Asp-
Glu-Val-Asp-fmk (zDEVD), z-Phe-Ala-fmk (zFA), z-Phe-Phe-fmk
(zFF), z-Leu-Leu-Leu-fmk (zLLL), E64d and CA-074, we were able
to implicate clan CA cysteine proteases in CQ-mediated PCD.
Conclusions: PCD pathways exist in P. falciparum and are broadly
similar to classical apoptosis pathways of mammalian cells, but
with some distinct differences. Malaria PCD pathways are medi-
ated by cysteine proteases belonging to clan CA instead of clan
CD, suggesting that PCD pathways converged in evolution and
that novel parasite-speciﬁc PCD mediators may be exploited in
antimalarial strategies.
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In order to search a molecular biomarker with low molecular
weight for the diagnosis of cysticercosis, cysticercuses from the
muscle of a naturally infected pig were isolated and collected.
Rough antigen was prepared from the cyst ﬂuid of the cysticercus
and used to immunize rabbits. General protein of the cyst ﬂuid
was analyzed by SDS-PAGE. Speciﬁc protein was identiﬁed with
Western Blot method by antiserum obtained from the immunized
rabbits. N-terminal amino acids of the identiﬁed protein were
detected and sequenced with Edman degradation. The results
demonstrated that a 16kDa protein with high speciﬁcity was
identiﬁed from the cyst ﬂuid of cysticercus and 10 amino acids
were detected in its N-terminal and sequenced as DLSKGEWQLV.
It is shown that the 16kDa protein has 80% identity to myoglobin.
It will be useful in the further study on the immunodiagnosis of
cysticercosis.
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Natural course of HCV infection: Previous studies including ours
indicate the progression of ﬁbrosis is steady but slow, and was es-
timated from 0.5 stages per year (normal-ALT) to 1.3. The efforts
to establish non-invasive measures including Fibroscan helped us
to relate the importance of liver ﬁbrosis or rather “stiffness” of
the liver to the development of HCC in a prospective fashion. To
the end, the slow down of ﬁbrosis progression or even reversal
could obviously anticipated to reduce the incidence of HCC.
Chronic hepatitis: In 1994, we set up a national surveillance pro-
gram for HCC development among chronic hepatitis C patients
and enrolled about 2,900 biopsy-proven cases. 2,400 of them
received interferon treatment, showing a sustained virologic re-
sponse rate of 33% on average. The risk of HCC was reduced by
half among the interferon-treated patients as a whole, and down
to one-ﬁfth among sustained virologic responders. Even among
the cirrhotic, the incidence of HCC was decreased by long term
follow-up. We also conﬁrmed histologically the resolution of cir-
rhosis following sustained virologic response and the calculated
rate of ﬁbrosis regression rate was 0.28 ﬁbrosis stage per year.
It was also shown that, not only the reduction of HCC incidence,
but also overall mortality including non-liver related death, was
decreased.
Anti-viral for HCC: It could be assumed that the anti-viral could
be only for prevention. However, our data clearly indicated that
the eradication of HCV in patients who already developed HCC
were also beneﬁcial to prolong the patients’ life. Now, we are
able to expect 80% 5-year survival rate in the combination of RFA
and the eradication of HCV.
